Avenue Therapeutics, Inc. (ATXI)

NASDAQ: ATXI · IEX Real-Time Price · USD
0.220
-0.031 (-12.46%)
At close: Jun 24, 2022 4:00 PM
0.244
+0.024 (10.682%)
After-hours: Jun 24, 2022 6:06 PM EDT
-12.46%
Market Cap 4.87M
Revenue (ttm) n/a
Net Income (ttm) -5.59M
Shares Out 22.13M
EPS (ttm) -0.31
PE Ratio n/a
Forward PE 17.99
Dividend n/a
Ex-Dividend Date n/a
Volume 327,783
Open 0.251
Previous Close 0.251
Day's Range 0.220 - 0.268
52-Week Range 0.200 - 2.810
Beta 1.05
Analysts Sell
Price Target n/a
Earnings Date n/a

About ATXI

Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York. [Read more...]

Industry Pharmaceuticals
IPO Date Jun 27, 2017
Employees 4
Stock Exchange NASDAQ
Ticker Symbol ATXI
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

No stock price forecast available yet.

Price Target
0
Analyst Consensus: Sell
Stock Forecasts

News

Top Biotech Penny Stocks to Buy Now? 3 to Watch in March

Check these three biotech penny stocks out for your watchlist The post Top Biotech Penny Stocks to Buy Now? 3 to Watch in March  appeared first on Penny Stocks to Buy, Picks, News and Information | Penn...

Other symbols: CLSDIBIO

Avenue Therapeutics Announces Outcome of FDA Advisory Committee Meeting on IV Tramadol

NEW YORK, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announced ...

Avenue Therapeutics Stock Trading Halted Today

FDA Advisory Committee to review IV tramadol New Drug Application FDA Advisory Committee to review IV tramadol New Drug Application

Aegis Capital Corp. Acted as Sole Bookrunner on a $2 Million Public Offering of Common Stock for Avenue Therapeutics ...

NEW YORK, NY / ACCESSWIRE / December 15, 2021 / Aegis Capital Corp. acted as Sole Bookrunner on a $2 Million Public Offering of Common Stock for Avenue Therapeutics (NASDAQ:ATXI). About Avenue Therapeut...

Avenue Therapeutics Announces Closing of Public Offering of Common Stock

NEW YORK, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (or the “Company”) (NASDAQ: ATXI), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today an...

Avenue Therapeutics Prices $2.0 Million Underwritten Public Offering of Common Stock

NEW YORK, Dec. 12, 2021 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announced ...

Best Penny Stocks Today: Why ATXI & PTPI Stock Are Moving

Shares of penny stocks PTPI & ATXI are on the move and here's what's going on. The post Best Penny Stocks Today: Why ATXI & PTPI Stock Are Moving appeared first on Penny Stocks to Buy, Picks, News and I...

Other symbols: PTPI

Avenue Therapeutics Announces Exercise and Closing of Underwriter's Over-Allotment Option

NEW YORK, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (the “Company”) (NASDAQ: ATXI), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today annou...

Aegis Capital Corp. acted as Sole Bookrunner on a $2.6 Million Public Offering of Common Stock for Avenue Therapeutic...

NEW YORK, NY / ACCESSWIRE / November 12, 2021 / Aegis Capital Corp. acted as Sole Bookrunner on a $2.6 Million Public Offering of Common Stock for Avenue Therapeutics (NASDAQ:ATXI). About Avenue Therape...

Avenue Therapeutics Prices $2.6 Million Underwritten Public Offering of Common Stock

NEW YORK, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announced ...

Avenue Therapeutics Receives Interim Response to its Formal Dispute Resolution Request from U.S. Food and Drug Admini...

Office of New Drugs concludes that additional input is needed, and U.S. Food and Drug Administration will convene an Advisory Committee meeting Office of New Drugs concludes that additional input is nee...

Why Novavax, Orphazyme, Avenue Therapeutics Shares Are Moving Monday

Novavax, Inc. (NASDAQ: NVAX), Orphazyme A/S (NASDAQ: ORPH) and Avenue Therapeutics, Inc. (NASDAQ: ATXI) are among the biggest movers among biopharma stocks Monday. Novavax Finally Releases Phase 3 COVID...

Other symbols: NVAX

Avenue Therapeutics Receives Complete Response Letter from the FDA for IV Tramadol

NEW YORK, June 14, 2021 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announced ...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Avenue Therapeutics, Inc. - ATXI

New York, New York--(Newsfile Corp. - April 21, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Avenue Therapeutics Inc. ("Avenue" or the "Company") (NASDAQ: ATXI). Such investor...

Avenue Therapeutics (ATXI) Sees Hammer Chart Pattern: Time to Buy?

Avenue Therapeutics (ATXI) has been struggling lately, but the selling pressure may be coming to an end soon

Avenue Therapeutics Announces that the FDA is Still Reviewing Its NDA Resubmission for IV Tramadol

The FDA Has Not Provided a Decision Regarding the NDA The FDA Has Not Provided a Decision Regarding the NDA

Avenue Therapeutics Announces Publication of Real-World Data on Nonmedical Use of Tramadol in ASI-MV Network

NEW YORK, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (Avenue), a company focused on the development of intravenous (IV) tramadol for the U.S. market, today announced that...

Avenue Therapeutics Announces Publication of Tramadol Non-Medical Use in Four European Countries: A Comparative Analysis

NEW YORK, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (Avenue), a company focused on the development of intravenous (IV) tramadol for the U.S. market, today announced that...

Avenue Therapeutics' Pain Drug Gets Complete Response Letter

Avenue Therapeutics' (ATXI) NDA seeking an approval for its pipeline candidate tramadol to treat postoperative pain gets a CRL from the FDA, based on potential safety concerns. Shares down.

Avenue Therapeutics Sinks As FDA Rejects Opioid Pain Drug On Safety Concerns

Shares of micro-cap biopharma Avenue Therapeutics Inc (NASDAQ: ATXI) are plummeting on above-average volume after a binary event panned out against the company. What Happened: New York-based Avenue said...

Avenue Therapeutics Announces Publication of a Review of IV Tramadol

NEW YORK, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announc...

Avenue Therapeutics (ATXI) Misses Earnings Estimates in Q2

Avenue Therapeutics (ATXI) reports a wider-than-expected loss in the second quarter of 2021.

Avenue Therapeutics Reports Second Quarter 2020 Financial Results and Recent Corporate Highlights

NEW YORK, Aug. 14, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today reported...

What's in Store for Avenue Therapeutics (ATXI) in Q2 Earnings?

Avenue Therapeutics' (ATXI) sole pipeline candidate, tramadol, is under review. With lower clinical activities, operating expenses are likely to have declined during the second quarter.

Avenue Therapeutics, Inc. (ATXI) Dips More Than Broader Markets: What You Should Know

Avenue Therapeutics, Inc. (ATXI) closed the most recent trading day at $10.30, moving -1.9% from the previous trading session.